Spondyloarthritis | Access and Reimbursement | US | 2016
The U.S. therapy market for the SpA indications PsA, AS, and nr-AxSpA is becoming increasingly crowded as new biologics and SMIs offering novel MOAs enter the market and compete for preferential formulary placement and market share against established TNF-α inhibitors. With the additional threat of biosimilar versions of market leaders on the horizon, this research aims to provide a detailed, expanded analysis of the market access environment for SpA in the United States. Insight on the interaction between physicians and payers, the impact of reimbursement decisions on drug uptake, and the expectations for emerging SpA therapies will help clarify the current—and future—state of the SpA therapy market for drug developers hoping to penetrate this space.
